Cantor Fitzgerald’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Cantor Fitzgerald’s Portfolio LABD Stock Details LABD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$831K	Buy	+51,000	New	+$965K	0.01%	187

Other funds holding LABD

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

CCM

Capstone Capital Management Hong Kong $224M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Cantor Fitzgerald's LABD Position: Q1 2026 in Review

Cantor Fitzgerald opened a new position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2026: 51,000 shares worth $831K. The stake represents 0.01% of the portfolio and ranks #187 among its holdings.

17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.

Cantor Fitzgerald held 51,000 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $831K as of Q1 2026.
Direxion Daily S&P Biotech Bear 3X ETF was a new Cantor Fitzgerald position in Q1 2026.
Direxion Daily S&P Biotech Bear 3X ETF made up 0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #187 holding.
17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.